CHRS — Coherus Oncology, Inc.
Is CHRS overbought or oversold? Here is the current MarketMoodz read.
Coherus Oncology, Inc. (CHRS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.51. The rating moved from Neutral to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.51
- Last changeMoved from Neutral to Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Coherus Oncology, Inc. (CHRS) exhibits characteristics of a high-risk, small-cap oncology issuer with limited public information and likely constrained liquidity. Market-wide flows are favoring large-cap, defensive pharma and M&A-active names, reducing near-term investor appetite for speculative oncology exposure. Key downside pressures include potential dilution, unclear cash runway, and binary clinical/regulatory outcomes; upside is binary and dependent on positive trial or partnership news.
Key factors
- Very low current share price and small-cap profile imply limited liquidity and higher volatility.
- Biotech/oncology sector facing investor preference for large-cap, defensive pharma which reduces appetite for small oncology developers.
- Industry theme of convertible-debt dilution and hedging pressure in mid/small-cap biotech raises probability of future equity issuance.
- Lack of recent EDGAR/filing analysis available increases uncertainty around cash runway and upcoming clinical/operational catalysts.
- Potential for partner deals or positive trial news could cause sharp, binary rallies, but such events are unpredictable.
- Macro risk-on tone favors growth and earnings momentum but is weighted toward larger, lower-risk healthcare names rather than speculative oncology names.
Risks
- Further equity dilution or debt financings that materially reduce shareholder value.
- Negative or inconclusive clinical trial results or regulatory setbacks for lead assets.
- Insufficient cash runway leading to accelerated fundraising at unfavorable terms.
- Limited analyst coverage and low retail/institutional interest, increasing bid-ask spreads and downside on sell pressure.
- Adverse sector rotations or funding market closures that restrict capital access.
- Operational execution issues (manufacturing, enrollment, partnerships) that delay milestones.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for CHRS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.